Ligand Pharmaceuticals Incorporated (LGND) reported core adjusted diluted net income per share of $1.20 in first-quarter 2024 from continuing operations. Although earnings declined 10$1.13. Total revenues of $31.0 million were down 30$32.5 million. The downside in earnings and sales was due to the receipt of a milestone payment from Travere Thera ...